Yun-Fan Liaw (Y-F Liaw, Y F Liaw)

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 41

Top Topics

Genome Wide Association

Hepatitis B Virus

Top Venues

Hepatology (Baltimore, Md.)

Alimentary pharmacology & therapeutics

Journal of viral hepatitis

Clinical and translational gastroenterology

This page only lists publications with an associated author ORCID identifier.

Publications

Yen-Chun Liu, Wen-Juei Jeng, Chien-Wei Peng, Rong-Nan Chien, Yun-Fan Liaw
Higher end-of-treatment HBsAg levels is associated with later onset but not severe relapse in HBeAg-negative chronic hepatitis B patients stopping antivirals. Alimentary pharmacology & therapeutics 59 (6) (2024)
Yi-Cheng Chen, Yun-Fan Liaw
Rapid HBsAg Decline Can Predict HBsAg Seroclearance Only in Patients With HBsAg <200 IU/mL. Clinical and translational gastroenterology 15 (3) (2024)
Yi-Cheng Chen, Yun-Fan Liaw
Rapid HBsAg Decline Can Predict HBsAg Seroclearance Only in Patients With HBsAg <200 IU/mL. Clinical and translational gastroenterology 15 (3) (2024)
Yen-Chun Liu, Wen-Juei Jeng, Chien-Wei Peng, Rong-Nan Chien, Yun-Fan Liaw
Higher end-of-treatment HBsAg levels is associated with later onset but not severe relapse in HBeAg-negative chronic hepatitis B patients stopping antivirals. Alimentary pharmacology & therapeutics 59 (6) (2024)
Yen-Chun Liu, Wen-Juei Jeng, Chien-Wei Peng, Rong-Nan Chien, Yun-Fan Liaw
Higher end-of-treatment HBsAg levels is associated with later onset but not severe relapse in HBeAg-negative chronic hepatitis B patients stopping antivirals. Alimentary pharmacology & therapeutics (2024)
Yen-Chun Liu, Wen-Juei Jeng, Chien-Wei Peng, Rong-Nan Chien, Yun-Fan Liaw
Higher end-of-treatment HBsAg levels is associated with later onset but not severe relapse in HBeAg-negative chronic hepatitis B patients stopping antivirals. Alimentary pharmacology & therapeutics (2024)
Cheng-Er Hsu, Yun-Fan Liaw
Hepatitis B Surface Antigen Kinetics After Tenofovir Withdrawal in Chronic Hepatitis B. The American journal of gastroenterology 119 (2) (2024)
Wen-Juei Jeng, Rong-Nan Chien, Yun-Fan Liaw
Reply: New confounders emerging with new evidence regarding reduced HCC and improved survival. Hepatology (Baltimore, Md.) (2024)
Yi-Cheng Chen, Yun-Fan Liaw
Rapid HBsAg Decline Can Predict HBsAg Seroclearance Only in Patients With HBsAg <200 IU/mL. Clinical and translational gastroenterology 15 (3) (2024)
Yen-Chun Liu, Wen-Juei Jeng, Chien-Wei Peng, Rong-Nan Chien, Yun-Fan Liaw
Higher end-of-treatment HBsAg levels is associated with later onset but not severe relapse in HBeAg-negative chronic hepatitis B patients stopping antivirals. Alimentary pharmacology & therapeutics 59 (6) (2024)
Cheng-Er Hsu, Yun-Fan Liaw
Hepatitis B Surface Antigen Kinetics After Tenofovir Withdrawal in Chronic Hepatitis B. The American journal of gastroenterology 119 (2) (2024)
Ming-Ling Chang, Yun-Fan Liaw
Emerging Therapies for Chronic Hepatitis B and the Potential for a Functional Cure. Drugs (2023)
Yun-Fan Liaw
Impact of ALT Changes on the Risk of HCC in Hepatitis B-Compensated Cirrhotic Patients With Low Viremia. The American journal of gastroenterology 118 (9) (2023)
Wen-Juei Jeng, Rong-Nan Chien, Yun-Fan Liaw
Reply: Halting antiviral therapy in patients with cirrhosis and chronic hepatitis B: A dangerous game? Hepatology (Baltimore, Md.) 79 (5) (2023)
Wen-Juei Jeng, Rong-Nan Chien, Yun-Fan Liaw
Reply: Halting antiviral therapy in patients with cirrhosis and chronic hepatitis B: A dangerous game? Hepatology (Baltimore, Md.) (2023)
Wen-Juei Jeng, Rong-Nan Chien, Yun-Fan Liaw
Reply: Halting antiviral therapy in patients with cirrhosis and chronic hepatitis B: A dangerous game? Hepatology (Baltimore, Md.) 79 (5) (2023)
Wei-Ting Chen, Shiu-Feng Kathy Huang, Ming-Ling Chang, Yun-Fan Liaw
Hepatocellular Carcinoma with Gastric Metastasis Mimicking a 4 cm Gastrointestinal Stromal Tumor After a 3-year Disease-free Interval. Journal of clinical and translational hepatology 12 (2) (2023)
Ming-Ling Chang, Yun-Fan Liaw
Hepatitis B Flare in Hepatitis B e Antigen-Negative Patients: A Complicated Cascade of Innate and Adaptive Immune Responses. International journal of molecular sciences 23 (3) (2022)
Yun-Fan Liaw
Hepatitis B flare: the good, the bad and the ugly. Expert review of gastroenterology & hepatology (2022)
Yun-Fan Liaw, Wen-Juei Jeng, Rong-Nan Chien
Hepatocellular carcinoma and HBsAg loss after cessation of antiviral therapy. Liver international : official journal of the International Association for the Study of the Liver 42 (4) (2022)
Ming-Ling Chang, Rong-Nan Chien, Yun-Fan Liaw
Robust antiviral responses in severe hepatitis flare persist after early retreatment cessation and lead toward hepatitis B surface antigen loss: A proof-of-concept study. Hepatology research : the official journal of the Japan Society of Hepatology 52 (10) (2022)
Yi-Tse Su, Ming-Ling Chang, Rong-Nan Chien, Yun-Fan Liaw
Hepatitis C Virus Reactivation in Anti-HCV Antibody-Positive Patients with Chronic Hepatitis B Following Anti-HBV Therapies. Viruses 14 (9) (2022)
Yen-Chun Liu, Wen-Juei Jeng, Chien-Wei Peng, Rong-Nan Chien, Yun-Fan Liaw
Off-tenofovir hepatitis flares in HBeAg-negative patients occur earlier, more frequent and severe than those off-entecavir therapies. Liver international : official journal of the International Association for the Study of the Liver 42 (3) (2022)
Yun-Fan Liaw
Perspectives on current controversial issues in the management of chronic HBV infection. Journal of gastroenterology 57 (11) (2022)
Rong-Nan Chien, Yun-Fan Liaw
Current Trend in Antiviral Therapy for Chronic Hepatitis B. Viruses 14 (2) (2022)
Yun-Fan Liaw, Rong-Nan Chien
Finite nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B: From an "option" to an "active recommendation". The Kaohsiung journal of medical sciences 38 (4) (2022)
Yun-Fan Liaw
Hepatitis B Flare After Cessation of Nucleos(t)ide Analogue Therapy in HBeAg-Negative Chronic Hepatitis B: To Retreat or Not to Retreat. Hepatology (Baltimore, Md.) 73 (2) (2021)
Yun-Fan Liaw
Retreatment decision for hepatitis B flare. Hepatology (Baltimore, Md.) (2020)
Rong-Nan Chien, Yun-Fan Liaw
Re-treatment for severe hepatitis flare in HBeAg-negative chronic hepatitis B: An appraisal with combined HBsAg/ALT kinetics. Journal of viral hepatitis 27 (5) (2020)
Chien-Wei Peng, Wen-Juei Jeng, Rong-Nan Chien, Yun-Fan Liaw
The impact of hepatitis flare on HBeAg loss was effective mainly in the first year of Nucleot(s)ide therapy in chronic hepatitis B. Journal of viral hepatitis 28 (3) (2020)
Chia-Ming Chu, Yun-Fan Liaw
Letter to the Editor: Age at Hepatitis B e Antigen Seroconversion and Other Factors for Outcomes of Chronic Hepatitis B. Hepatology (Baltimore, Md.) 69 (6) (2019)
Lai Wei, Vedran Pavlovic, Aruna T Bansal, Xiaoping Chen, Graham R Foster, Hua He, Jia-Horng Kao, Pietro Lampertico, Yun-Fan Liaw, Adriana Motoc, Georgios Papatheodoridis, Teerha Piratvisuth, Robert Plesniak, Cynthia Wat
Genetic variation in FCER1A predicts peginterferon alfa-2a-induced hepatitis B surface antigen clearance in East Asian patients with chronic hepatitis B. Journal of viral hepatitis 26 (9) (2019)
Wen-Juei Jeng, Ming-Ling Chang, Yun-Fan Liaw
Off-therapy precipitous HBsAg decline predicts HBsAg loss after finite entecavir therapy in HBeAg-negative patients. Journal of viral hepatitis 26 (8) (2019)
Yun-Fan Liaw, Wen-Juei Jeng
Benefit of stopping finite nucleos(t)ide analogues therapy in chronic hepatitis B patients. Gut 69 (10) (2019)
Yun-Fan Liaw
Finite nucleos(t)ide analog therapy in HBeAg-negative chronic hepatitis B: an emerging paradigm shift. Hepatology international 13 (6) (2019)
Yun-Fan Liaw
Clinical utility of HBV surface antigen quantification in HBV e antigen-negative chronic HBV infection. Nature reviews. Gastroenterology & hepatology 16 (10) (2019)
W-L Chuang, J Jia, Henry Lik Yuen Chan, K-H Han, T Tanwandee, D Tan, X Chen, E Gane, T Piratvisuth, L Chen, Q Xie, J J-Y Sung, D Messinger, C Wat, G Bakalos, Yun-Fan Liaw
Responses are durable for up to 5 years after completion of peginterferon alfa-2a treatment in hepatitis B e antigen-positive patients. Alimentary pharmacology & therapeutics 47 (9) (2018)
Wen-Juei Jeng, Yi-Cheng Chen, Rong-Nan Chien, I-Shyan Sheen, Yun-Fan Liaw
Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B. Hepatology (Baltimore, Md.) 68 (2) (2018)
Shiu-Feng Huang, Il-Chi Chang, Chih-Chen Hong, Tseng-Chang Yen, Chao-Long Chen, Cheng-Chung Wu, Cheng-Chung Tsai, Ming-Chih Ho, Wei-Chen Lee, Hsien-Chung Yu, Ying-Ying Shen, Hock-Liew Eng, John Wang, Hui-Hwa Tseng, Yung-Ming Jeng, Chau-Ting Yeh, Chi-Ling Chen, Pei-Jer Chen, Yun-Fan Liaw
Metabolic risk factors are associated with non-hepatitis B non-hepatitis C hepatocellular carcinoma in Taiwan, an endemic area of chronic hepatitis B. Hepatology communications 2 (6) (2018)
Chia-Ming Chu, Yun-Fan Liaw
Prognosis of immune-tolerant phase chronic hepatitis B. Gut 67 (5) (2017)
W-J Jeng, Yi-Cheng Chen, Yun-Fan Liaw
Great and rapid HBsAg decline in patients with on-treatment hepatitis flare in early phase of potent antiviral therapy. Journal of viral hepatitis 25 (4) (2017)